- Home
- GH vs LUMN Comparison
GH vs LUMN Comparison
Compare GH & LUMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GH
- LUMN
- Stock Information
- Founded
- GH 2011
- LUMN 1968
- Country
- GH United States
- LUMN United States
- Employees
- GH N/A
- LUMN N/A
- Industry
- GH Medical Specialities
- LUMN Telecommunications Equipment
- Sector
- GH Health Care
- LUMN Telecommunications
- Exchange
- GH Nasdaq
- LUMN Nasdaq
- Market Cap
- GH 4.9B
- LUMN 4.1B
- IPO Year
- GH 2018
- LUMN 1972
- Fundamental
- Price
- GH $50.00
- LUMN $4.59
- Analyst Decision
- GH Strong Buy
- LUMN Hold
- Analyst Count
- GH 20
- LUMN 9
- Target Price
- GH $54.35
- LUMN $4.78
- AVG Volume (30 Days)
- GH 2.1M
- LUMN 11.8M
- Earning Date
- GH 08-06-2025
- LUMN 08-05-2025
- Dividend Yield
- GH N/A
- LUMN N/A
- EPS Growth
- GH N/A
- LUMN N/A
- EPS
- GH N/A
- LUMN N/A
- Revenue
- GH $773,996,000.00
- LUMN $13,000,000,000.00
- Revenue This Year
- GH $23.14
- LUMN N/A
- Revenue Next Year
- GH $21.42
- LUMN N/A
- P/E Ratio
- GH N/A
- LUMN N/A
- Revenue Growth
- GH 28.20
- LUMN N/A
- 52 Week Low
- GH $20.14
- LUMN $1.00
- 52 Week High
- GH $53.42
- LUMN $10.33
- Technical
- Relative Strength Index (RSI)
- GH 60.59
- LUMN 63.75
- Support Level
- GH $48.07
- LUMN $4.34
- Resistance Level
- GH $53.42
- LUMN $4.59
- Average True Range (ATR)
- GH 2.25
- LUMN 0.21
- MACD
- GH -0.12
- LUMN 0.04
- Stochastic Oscillator
- GH 55.56
- LUMN 86.65
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
About LUMN Lumen Technologies Inc.
With 450,000 route miles of fiber, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 in 2017 and divestiture of much of its incumbent local exchange carrier, or ILEC, business in 2022 have shifted the company's operations away from its legacy consumer business and toward enterprises (now about 75% of revenue). Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen has announced the sale of its consumer fiber network, but will maintain and harvest its legacy consumer copper network.